Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire
Authors:
- 1 April 2022
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 81 (4) , 507-515
Abstract
Objectives Patient-reported outcome measures (PROMs) are important for clinical practice and research. Given the high unmet need, our aim was to develop a comprehensive PROM for systemic sclerosis (SSc), jointly with patient experts. Methods This European Alliance of Associations for Rheumatology (EULAR)-endorsed project involved 11 European SSc centres. Relevant health dimensions were chosen and prioritised by patients. The resulting Systemic Sclerosis Impact of Disease (ScleroID) questionnaire was subsequently weighted and validated by Outcome Measures in Rheumatology criteria in an observational cohort study, cross-sectionally and longitudinally. As comparators, SSc-Health Assessment Questionnaire (HAQ), EuroQol Five Dimensional (EQ-5D), Short Form-36 (SF-36) were included. Results Initially, 17 health dimensions were selected and prioritised. The top 10 health dimensions were selected for the ScleroID questionnaire. Importantly, Raynaud’s phenomenon, impaired hand function, pain and fatigue had the highest patient-reported disease impact. The validation cohort study included 472 patients with a baseline visit, from which 109 had a test–retest reliability visit and 113 had a follow-up visit (85% female, 38% diffuse SSc, mean age 58 years, mean disease duration 9 years). The total ScleroID score showed strong Pearson correlation coefficients with comparators (SSc-HAQ, 0.73; Patient’s global assessment, Visual Analogue Scale 0.77; HAQ-Disability Index, 0.62; SF-36 physical score, −0.62; each pConclusions We have developed and validated the EULAR ScleroID, which is a novel, brief, disease-specific, patient-derived, disease impact PROM, suitable for research and clinical use in SSc.Keywords
Funding Information
- European League Against Rheumatism (EULAR Project CLI083)
This publication has 36 references indexed in Scilit:
- Development and preliminary validation of the pancreatic cancer disease impact scoreSupportive Care in Cancer, 2013
- Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID)Arthritis Research & Therapy, 2012
- Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiativeAnnals of the Rheumatic Diseases, 2011
- Discordance between Patient and Physician Assessments of Disease Severity in Systemic SclerosisThe Journal of Rheumatology, 2010
- Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiativeAnnals of the Rheumatic Diseases, 2009
- On the Use, the Misuse, and the Very Limited Usefulness of Cronbach’s AlphaPsychometrika, 2009
- Work Disability in Scleroderma is Greater than in Rheumatoid Arthritis and is Predicted by High HAQ ScoresThe Open Rheumatology Journal, 2008
- Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group databaseAnnals of the Rheumatic Diseases, 2007
- Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptomsClinical Rheumatology, 2004
- Validation of French version of the Scleroderma Health Assessment Questionnaire (SSc HAQ)Clinical Rheumatology, 2004